Immunology of Allergic Airway Diseases

Allergies have a similar immunological profile constituted up of recognizable cells, antibodies, and other biochemical and molecular structures. It is simple to identify eosinophils, neutrophils, and tissue mast cells using standard hematoxylin and eosin staining of histologic tissues. Symptoms of allergic respiratory disorders including hay fever (allergic rhinoconjunctivitis) and asthma include wet or itchy eyes, sneezing, nasal congestion, and coughing; these conditions are the result of a persistent inflammatory process. In theory, the best treatment for allergic illness would eliminate the triggers that cause it. Allergen-specific immunotherapy, which has been used for many years, is based in part on this principle. Omalizumab, a monoclonal antibody treatment that depletes circulating IgE to gradually lower the quantity of antibody attached to high-affinity IgE receptors on mast cells, is a promising example of the success that may be achieved by adopting a different approach. However, patient access to therapy in chronic illnesses affecting large populations is complicated by major payment hurdles associated with biologic medicines like omalizumab. The present study aims to examine the mechanisms by which a prominent allergen mediated allergic responses and explore potential interventions to mitigate the immune overactivation associated with allergic airway disorders caused by these allergens.